Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma

Cornea

Volumn 26, Issue 1, 2007, Pages 34-41

  Harasymowycz, Paul J ^a,c   Papamatheakis, Demosthenes G ^a   Ennis, Marguerite ^b   Brady, Mary ^c   Gordon, Keith D ^c   Archambault, P ^b   Bazin, G ^b   Boucher, S ^b   Brochu, J ^b   Charbonneau, A ^b   Chehade N ^b   Cohen, S ^b   Deschenes, C ^b   Gelinas, G ^b   Gosselin, M ^b   Hasegawa, N ^b   Isabelle, N ^b   Kavalec, C ^b   Krauss, D ^b   Lalonde, G ^b   Lalonde, L ^b   Lapointe, A ^b   Mayer, J ^b   Noel, F ^b   Podtetenev, M ^b   Robrerge, M ^b   Simard, M ^b   Weldon, C ^b   more..

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Alcon Canada Inc ^*

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Central corneal thickness; Glaucoma; Intraocular pressure; Prostaglandins; Travoprost

Indexed keywords

TRAVOPROST;

ADULT; AGED; ARTICLE; BLURRED VISION; CANADA; CLINICAL TRIAL; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CORNEA THICKNESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HAIR GROWTH; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NAUSEA; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; VOMITING;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CORNEA; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TONOMETRY, OCULAR;

EID: 33846003126     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31802e3ce4     Document Type: Article

References (33)

1. Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138(Suppl):19-31.
2. Parrish RK, Palmberg P, Sheu WP. the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
3. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112-115.
4. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2a treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794-801.
5. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
6. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/ timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004;20:1333-1339.
7. Kaback M, Geanon J, Katz G. the START Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin. 2004;20:1341-1345.
8. Przydryga JT, Egloff C. the Swiss Start Study Group. Intraocular pressure lowering efficacy of travoprost. Eur J Ophthalmol. 2004;14:416-422.
9. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
10. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(Suppl):105-115.
11. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-163.
12. Netland P, Landry T, Sullivan R, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
13. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120:714-720.
14. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol. 2004;122:17-21.
15. Shih CY, Graff Zivin JS, Trokel SL, et al. Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol. 2004;122:1270-1275.
16. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
17. Inoue K, Okugawa K, Oshika T, et al. Influence of dorzolamide on corneal endothelium. Jpn J Ophthalmol. 2003;47:129-133.
18. 2α-analogues and carbonic anhydrase inhibitors on central corneal thickness - a cross-sectional study on 403 eyes. Klin Monatsbl Augenheilkd. 2004;221:753-756.
19. Lass JH, Eriksson GL, Osterling L, et al. the Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked randomized, one-year study. Ophthalmology. 2001;108:264-271.
20. Alcon Laboratories. Travatan (travoprost ophthalmic solution) 0.004% Sterile. Available at: http://ecatalog.alcon.com/pi/Travatan_US_en.pdf. Accessed December 24, 2004.
21. Carroll RJ, Ruppert D. The use and misuse of orthogonal regression in linear errors-in-variables models. Am Stat. 1996;50:1-6.
22. Sihota R, Saxena R, Agarwal HC, et al. Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. Arch Ophthalmol. 2004;122:185-189.
23. Januleviciene I, Harris A, Kagemann L, et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82:730-737.
24. Fuller WA. Measurement Error Models. New York: John Wiley & Sons; 1987.
25. Bland JM, Altman DG. Statistics notes: some examples of regression towards the mean. BMJ. 1994;309:780.
26. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141-1164.
27. Chuang-Stein C, Tong DM. The impact and implication of regression to the mean on the design and analysis of medical investigations. Stat Methods Med Res. 1997;6:115-128.
28. Gordon MO, Schechtman KB, Li Z, et al. A protocol to minimize bias and regression to the mean in measurement of intraocular pressure. Control Clin Trials. 1995;16(Suppl):98-99.
29. Wickham L, Edmunds B, Murdoch IE. Central corneal thickness: will one measurement suffice? Ophthalmology. 2005;112:225-228.
30. Smith VA, Hoh HB, Littleton M, et al. Overexpression of gelatinase A activity in keratoconus. Eye. 1995;9:429-433.
31. Wang N, Lindsey JD, Angert M, et al. Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures. Curr Eye Res. 2001;22:198-207.
32. Brandt JD, Beiser JA, Gordon MO, et al. the Ocular Hypoertension Treatment study (OHTS) Groups. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138:717-722.
33. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001;131:798-799.